ReviewLeukemia2009
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Review in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Leukemia · 2013Pooled it
- Trial
- A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.Bone marrow transplantation · 2011Trial
- Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis.World journal of oncology · 2023Article
- Imaging CXCR4 receptors expression for staging multiple myeloma by usingThe British journal of radiology · 2022Article
- Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers.Frontiers in medicine · 2021Review
- Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.BMC cancer · 2015Article
- The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.Journal of hematology & oncology · 2015Article
- Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.Experimental hematology & oncology · 2015Article
- Article
- Article
- Vesiculovirus neutralization by natural IgM and complement.Journal of virology · 2014Article
- The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma.Blood research · 2013Article
- PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Journal of virology · 2013Article
- MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.Blood cancer journal · 2013Article
- Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation.Mediterranean journal of hematology and infectious diseases · 2013Article
- New proteasome inhibitors in myeloma.Current hematologic malignancy reports · 2012Review
- Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Experimental hematology & oncology · 2012Article
- Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling.Journal of molecular medicine (Berlin, Germany) · 2012Article
- Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.Cancer gene therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.